Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Department of Neurosurgery, Jiujiang No. 1 People's Hospital, Jiujiang, China.
Front Immunol. 2024 Nov 1;15:1476436. doi: 10.3389/fimmu.2024.1476436. eCollection 2024.
Glioma is one of the common tumors in the central nervous system, and its treatment methods (surgery, radiotherapy, and chemotherapy) lack specificity and have a poor prognosis. With the development of immunology, cell biology, and genomics, tumor immunotherapy has ushered in a new era of tumor therapy, achieving significant results in other invasive cancers such as advanced melanoma and advanced non-small cell lung cancer. Currently, the clinical trials of immunotherapy in glioma are also progressing rapidly. Here, this review summarizes promising immunotherapy methods in recent years, reviews the current status of clinical trials, and discusses the challenges and prospects of glioma immunotherapy.
脑胶质瘤是中枢神经系统常见的肿瘤之一，其治疗方法（手术、放疗、化疗）缺乏特异性，预后较差。随着免疫学、细胞生物学和基因组学的发展，肿瘤免疫治疗迎来了肿瘤治疗的新时代，在晚期黑色素瘤和晚期非小细胞肺癌等侵袭性癌症中取得了显著成效。目前，脑胶质瘤的免疫治疗临床试验也在快速推进。在此，本文综述近年来有前景的免疫治疗方法，回顾目前的临床试验现状，并探讨脑胶质瘤免疫治疗所面临的挑战和前景。
